A pilot randomized feasibility clinical trial of intranasal vs. intravenous naloxone in pediatric opioid poisoning.

Drug Alcohol DependJul 3, 2026 (epub)
Clinical ResearchPediatricsEmergency Medicine

Narges Gholami, Arne Kristian Skulberg, Fariba Farnaghi et al.

✦ AI-curated · Sources linked

In 30 seconds

This pilot randomized feasibility trial assessed intranasal (IN) versus intravenous (IV) naloxone in children aged 1-12 years with opioid poisoning. Conducted at a Tehran hospital, the study found that the median time to response was significantly shorter for IN naloxone at 24 seconds compared to 65 seconds for IV naloxone. All participants responded to naloxone treatment.

Key findings

  • Median time to response was 24s for IN naloxone versus 65s for IV naloxone.
  • Thirty-nine children were randomized, with all responding to naloxone.
  • Over 90% satisfaction reported by parents and healthcare providers.
  • All participants adhered to the study protocol.

Why it matters

The findings suggest that intranasal naloxone may provide a quicker response in pediatric opioid poisoning, which is critical in emergency situations. Understanding the feasibility of this route can inform future treatment protocols.

Source

PubMed · PMID 42413284

Published in Drug Alcohol Depend. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.